Quality and performance

Trust stops making cancer drugs after criticism from regulator

By 2019-11-04T13:01:00

Royal Surrey

An acute trust is to abandon manufacturing its own radiopharmaceuticals after a regulator said it needed more quality improvement work and better facilities.

You need to be a subscriber to read more

HSJ

Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All HSJ news by sector, topic & region
  • Breaking News announcements
  • App for mobile and offline reading
  • Comment and Daily Insights newsletters
  • Regional roundup newsletters
  • Unrestricted access to ‘Ask HSJ’ - AI assistant - AI assistant
  • 10 expert briefings every fortnight (Premium only)

Subscribe

to HSJ

Already a subscriber? Sign into your account here